Suchergebnisse - "Lenalidomide"

PubPharm (5.975)

91

Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma : pooled analysis of three clinical trials

enthalten in: Scientific reports | 2024

von Almansour, S. | Alqudah, M. | Abuhelwa, Z. | +8

92

A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients : a report from the Triveneto Myeloma Working Group

enthalten in: Annals of hematology | 2024

von Barilà, G. | Quaglia, F. | Furlan, A. | +21

93

Maintenance therapy for chronic lymphocytic leukaemia

enthalten in: The Cochrane database of systematic reviews | 2024

von Lee, C. | Wu, Y. | Huang, T. | +6

94

Induced protein degradation for therapeutics : past, present, and future

enthalten in: The Journal of clinical investigation | 2024

von Yoon, H. | Rutter, J. | Li, Y. | +1

95

Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report

in: Surgical Case Reports | 2024

von Koki Tamai | Hajime Hirose | Yo Akazawa | +7

96

Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma

in: Discover Oncology | 2024

von Yang Liu | Yanju Li | Chike Zhang | +11

97

Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma

in: Pathogens | 2024

von Alpay Yeşilaltay | Dilek Muz | Berna Erdal | +6

98

Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial

in: BMC Cancer | 2024

von Graham McIlroy | Siân Lax | Charlotte Gaskell | +12

99

Complete Remission in a TEMPI Syndrome Treated with a Daratumumab, Lenalidomide, and Dexamethasone-Based Regimen: A Case Report

in: Case Reports in Oncology | 2024

von Pierre-Yves Sansen | Luc Montfort | Anne Nanquette | +2

100

Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma

enthalten in: Anti-cancer drugs | 2024

von Alhaj Moustafa, M. | Parrondo, R. | Abdulazeez, M. | +15